Drugs / B7-1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00031564 | May 2000 → Jun 2005 | kidney cancer | H. Lee Moffitt Cancer Center and Research Institute | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | B7-1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00031564 ↗ |
| Modality | Vaccine | “B7-1 gene-modified autologous tumor cell vaccine” NCT00031564 ↗ |
| Route | Subcutaneous | “B7-1 gene-modified autologous tumor cell vaccine subcutaneously (SC) once on days 1, 29, and 57” NCT00031564 ↗ |